Display options
Cite
Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. GREAT Group. BMJ. 1992;305(6853):548-53doi: 10.1136/bmj.305.6853.548.
(1992). Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. GREAT Group. BMJ (Clinical research ed.), 305(6853), 548-53. https://doi.org/10.1136/bmj.305.6853.548
"Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. GREAT Group." BMJ (Clinical research ed.) vol. 305,6853 (1992): 548-53. doi: https://doi.org/10.1136/bmj.305.6853.548
Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. GREAT Group. BMJ. 1992 Sep 05;305(6853):548-53. doi: 10.1136/bmj.305.6853.548. PMID: 1393033; PMCID: PMC1883310.
Copy Download .nbib Format: NLM
Share it on

BMJ. 1992 Sep 05;305(6853):548-53. doi: 10.1136/bmj.305.6853.548.

Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. GREAT Group.

BMJ (Clinical research ed.)

[No authors listed]

PMID: 1393033 PMCID: PMC1883310 DOI: 10.1136/bmj.305.6853.548
Free PMC Article

Abstract

OBJECTIVE: To assess the feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners.

DESIGN: Randomised double blind parallel group trial of anistreplase 30 units intravenously and placebo given either at home or in hospital.

SETTING: 29 rural practices in Grampian admitting patients to teaching hospitals in Aberdeen (average distance 36 (range 16-62) miles).

PATIENTS: 311 patients with suspected acute myocardial infarction and no contraindications to thrombolytic therapy seen at home within four hours of onset of symptoms.

MAIN OUTCOME MEASURES: Time saving, adverse events, Q wave infarction, left ventricular function.

RESULTS: Anistreplase was administered at home 101 minutes after onset of symptoms, while anistreplase was given in hospital 240 minutes after onset of symptoms (median times). Adverse events after thrombolysis were infrequent and, apart from cardiac arrest, not a serious problem when they occurred in the community: seven of 13 patients were resuscitated after cardiac arrest out of hospital. By three months after trial entry the relative reduction of deaths from all causes in patients given thrombolytic therapy at home was 49% (13/163 (8.0%) v 23/148 (15.5%); difference -7.6% (95% confidence interval -14.7% to -0.4%), p = 0.04). Full thickness Q wave infarction was less common in patients with confirmed infarction receiving treatment at home (65/122 (53.3%) v 76/112 (67.9%); difference -14.6% (95% confidence interval -27.0% to -2.2%), p = 0.02).

CONCLUSIONS: General practitioners provided rapid pre-hospital coronary care of a high standard. Compared with later administration in hospital, giving anistreplase at home resulted in reduction in mortality, fewer cardiac arrests, fewer Q wave infarcts, and better left ventricular function. Benefits were most marked where thrombolytic therapy was administered within two hours of the onset of symptoms.

Similar articles

Chamberlain D.
Curr Opin Anaesthesiol. 1999 Apr;12(2):179-82. doi: 10.1097/00001503-199904000-00012.
PMID: 17013311

Cited by

References

  1. Eur Heart J. 1982 Dec;3(6):504-15 - PubMed
  2. Am J Med. 1982 Oct;73(4):573-81 - PubMed
  3. Br Heart J. 1985 Feb;53(2):123-9 - PubMed
  4. Br Med J (Clin Res Ed). 1987 Sep 12;295(6599):639-40 - PubMed
  5. Lancet. 1992 May 9;339(8802):1167 - PubMed
  6. BMJ. 1991 Jun 22;302(6791):1517-20 - PubMed
  7. BMJ. 1990 Aug 11;301(6747):321-2 - PubMed
  8. Lancet. 1989 Jun 17;1(8651):1371-3 - PubMed
  9. Br Med J (Clin Res Ed). 1987 Feb 7;294(6568):352-4 - PubMed
  10. Br Med J (Clin Res Ed). 1988 Mar 26;296(6626):882-4 - PubMed
  11. Lancet. 1967 Aug 5;2(7510):271-3 - PubMed
  12. Am J Med. 1975 Feb;58(2):151-65 - PubMed
  13. Br Heart J. 1992 Mar;67(3):255-62 - PubMed
  14. BMJ. 1991 Jun 1;302(6788):1287-8 - PubMed
  15. BMJ. 1990 Nov 24;301(6762):1219 - PubMed
  16. Br Heart J. 1990 May;63(5):267-72 - PubMed
  17. Lancet. 1985 Feb 23;1(8426):441-4 - PubMed
  18. Lancet. 1988 Sep 3;2(8610):525-30 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources